These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 3931643)

  • 61. Pharmacology of binding of 3H-SCH-23390 to D-1 dopaminergic receptor sites in rat striatal tissue.
    Faedda G; Kula NS; Baldessarini RJ
    Biochem Pharmacol; 1989 Feb; 38(3):473-80. PubMed ID: 2563653
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: a key to receptor regulatory mechanisms.
    Norman AB; Battaglia G; Creese I
    J Neurosci; 1987 May; 7(5):1484-91. PubMed ID: 2952771
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain.
    Levant B; Grigoriadis DE; DeSouza EB
    J Pharmacol Exp Ther; 1992 Sep; 262(3):929-35. PubMed ID: 1356154
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of neuroleptic binding characteristics in rat striatum and renal cortex.
    Hietala J; Syvälahti E; Röyttä M
    J Recept Res; 1988; 8(6):753-71. PubMed ID: 3193400
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evidence for the importance of a carboxyl group in the binding of ligands to the D2 dopamine receptor.
    Williamson RA; Strange PG
    J Neurochem; 1990 Oct; 55(4):1357-65. PubMed ID: 2144583
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dissociation of receptor-bound human chorionic gonadotropin from rat testicular membranes in vitro as a high molecular weight complex and its inhibition by heavy metals and alkylating agents.
    Kellokumpu S; Rajaniemi H
    Biochim Biophys Acta; 1982 Sep; 718(1):26-34. PubMed ID: 6291621
    [No Abstract]   [Full Text] [Related]  

  • 67. Endurance training effects on striatal D2 dopamine receptor binding and striatal dopamine metabolite levels.
    MacRae PG; Spirduso WW; Cartee GD; Farrar RP; Wilcox RE
    Neurosci Lett; 1987 Aug; 79(1-2):138-44. PubMed ID: 2959886
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A novel affinity purification of D-1 dopamine receptors from rat striatum.
    Sidhu A
    J Biol Chem; 1990 Jun; 265(17):10065-72. PubMed ID: 2141020
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cerebellar and striatal dopamine receptors: effects of reeler and weaver murine mutations.
    Panagopoulos NT; Matsokis NA; Valcana T
    J Neurosci Res; 1993 Aug; 35(5):499-506. PubMed ID: 8377223
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes.
    Ferre S; von Euler G; Johansson B; Fredholm BB; Fuxe K
    Proc Natl Acad Sci U S A; 1991 Aug; 88(16):7238-41. PubMed ID: 1678519
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vivo [3H]spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization.
    Chugani DC; Ackermann RF; Phelps ME
    J Cereb Blood Flow Metab; 1988 Jun; 8(3):291-303. PubMed ID: 2966803
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dopamine D-2 receptors in canine brain: ionic effects on [3H]neuroleptic binding.
    Jarvie KR; Niznik HB; Seeman P
    Eur J Pharmacol; 1987 Dec; 144(2):163-71. PubMed ID: 2893738
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [3H]spiperone and [3H]quinuclidinyl benzilate binding in striatal membranes from rats chronically treated with manganese chloride throughout development and for over two years.
    Leung TK; Lai JC; Lim L
    Gen Pharmacol; 1986; 17(1):121-3. PubMed ID: 3949146
    [TBL] [Abstract][Full Text] [Related]  

  • 74. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [3H]Ro 22-1319 (piquindone) binds to the D2 dopaminergic receptor subtype in a sodium-dependent manner.
    Nakajima T; Iwata K
    Mol Pharmacol; 1984 Nov; 26(3):430-8. PubMed ID: 6149457
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evidence for the existence of receptor--receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides.
    Fuxe K; Agnati LF; Benfenati F; Celani M; Zini I; Zoli M; Mutt V
    J Neural Transm Suppl; 1983; 18():165-79. PubMed ID: 6192208
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Striatal D1- and D2-dopamine receptor sites are separately detectable in vivo.
    Leslie CA; Bennett JP
    Brain Res; 1987 Jul; 415(1):90-7. PubMed ID: 2957025
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Thermodynamic differences between agonist and antagonist interactions with binding sites for [3H]spiroperidol in rat striatum.
    Zahniser NR; Molinoff PB
    Mol Pharmacol; 1983 Mar; 23(2):303-9. PubMed ID: 6835199
    [TBL] [Abstract][Full Text] [Related]  

  • 79. N-linked oligosaccharides are responsible for rat striatal dopamine D2 receptor heterogeneity.
    Clagett-Dame M; McKelvy JF
    Arch Biochem Biophys; 1989 Oct; 274(1):145-54. PubMed ID: 2528326
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [3H]Fluphenazine binding to brain membranes: simultaneous measurement of D-1 and D-2 receptor sites.
    Morgan DG; Finch CE
    J Neurochem; 1986 May; 46(5):1623-31. PubMed ID: 2937884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.